Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 3,231 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Solution Clear all
Completed Phase 3 Interventional Results available

SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.

NCT03131154
View directory record Official record
Conditions
Non-infectious Anterior Uveitis
Interventions
ADX-102 Ophthalmic Solution (0.5%), Vehicle of ADX-102 Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Prescott, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 30, 2026, 3:16 PM EDT
Recruiting Phase 2 Interventional

A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

NCT04042844
View directory record Official record
Conditions
Lumbar Disc Disease
Interventions
BRTX-100, Saline
Biological · Drug
Lead sponsor
BioRestorative Therapies
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Santa Monica, California • Walnut Creek, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pectoral Fascial Plane and Serratus Anterior Plane Blocks With Bupivacaine v. Liposomal Bupivacaine

NCT03731221
View directory record Official record
Conditions
Video Assisted Thoracic Surgery
Interventions
Bupi HCI and lipo bupi, Bupi HCI
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 30, 2026, 3:16 PM EDT
Withdrawn Phase 2 Interventional

Effect of Perioperative Intravenous Lidocaine on Postoperative Quality of Recovery in Patients Undergoing Spine Surgery

NCT01930877
View directory record Official record
Conditions
Pain
Interventions
Lidocaine, Placebo (normal saline)
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Phase 3 Interventional Results available

The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

NCT03879863
View directory record Official record
Conditions
Dry Eye
Interventions
Reproxalap Ophthalmic Solution (0.25%) QID, Vehicle Ophthalmic Solution QID, Reproxalap Ophthalmic Solution (0.25%) QID to BID, Vehicle Ophthalmic Solution QID to BID
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation

NCT00224406
View directory record Official record
Conditions
Ischemia-Reperfusion Injury, Lung Transplantation
Interventions
Repertaxin, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 65 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Los Angeles, California • Denver, Colorado • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 30, 2026, 3:16 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Validation of Texture Changing Coatings for Use in At-Home Rapid Tests

NCT06539728
View directory record Official record
Conditions
Vision, Low, Blindness
Interventions
Interaction with Mock COVID-19 Rapid Antigen Test and Reference Surfaces, Biomechanical Measurements, Psychophysical Tasks
Diagnostic Test · Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 30, 2026, 3:16 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of ATX-01 in Participants With DM1

NCT06300307
View directory record Official record
Conditions
Myotonic Dystrophy 1
Interventions
ATX-01, Placebo
Drug
Lead sponsor
ARTHEx Biotech S.L.
Industry
Eligibility
18 Years to 64 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis

NCT01809132
View directory record Official record
Conditions
Acute Alcoholic Hepatitis
Interventions
Anakinra, Pentoxifylline, Zinc Sulfate, Methylprednisolone
Drug
Lead sponsor
Mack Mitchell
Other
Eligibility
21 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Louisville, Kentucky • Worcester, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in Patients Undergoing LVAD Implantation

NCT01442129
View directory record Official record
Conditions
Heart Failure, Cardiomyopathy, Ventricular Dysfunction
Interventions
MPC Intramyocardial injection, Control Solution
Biological
Lead sponsor
Deborah Ascheim
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Gainsville, Florida • Baltimore, Maryland • Minneapolis, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Phase 3 Interventional

Pilot: Intraoperative TAP Block and Post-operative Pain Control for Minimally Invasive Hysterectomy for Endometrial Cancer

NCT05763667
View directory record Official record
Conditions
Post Operative Pain, Gynecologic Cancer
Interventions
Liposomal bupivacaine, Bupivacain
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

NCT03373435
View directory record Official record
Conditions
Postbariatric Hypoglycemia
Interventions
exendin 9-39, Placebo
Drug · Other
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Palo Alto, California • Aurora, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 30, 2026, 3:16 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps

NCT02134925
View directory record Official record
Conditions
Colorectal Adenoma, Colorectal Carcinoma, Colorectal Conventional Adenoma With Severe Dysplasia, Colorectal Tubulovillous Adenoma
Interventions
Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine, Quality-of-Life Assessment, Saline
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • Rochester, Minnesota • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Phase 1Phase 2 Interventional

Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)

NCT01473264
View directory record Official record
Conditions
Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Interventions
recombinant human CC10 (rhCC10), placebo
Drug
Lead sponsor
Clarassance, Inc.
Industry
Eligibility
24 Weeks to 29 Weeks
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
4
States / cities
Wilmington, Delaware • Baltimore, Maryland • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

NCT04032093
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
RSV vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
1,153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
145
States / cities
Birmingham, Alabama • Cullman, Alabama • Glendale, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

Ultrasound-guided Femoral Nerve Blocks in Elderly Patients With Hip Fractures

NCT01701414
View directory record Official record
Conditions
Femoral Neck Fractures, Hip Fractures
Interventions
Femoral nerve block: 25 mL of 0.5% bupivacaine, Placebo: 3cc of 0.9% Normal Saline
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
55 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Phase 4 Interventional Results available

Liposomal Bupivacaine After Arthroscopic Rotator Cuff Repair

NCT03149887
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
Liposomal bupivacaine, Placebo
Drug
Lead sponsor
Steven Orebaugh
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

EXPAREL for Minimally Invasive Supracervical Hysterectomies

NCT03769714
View directory record Official record
Conditions
Pain
Interventions
Saline Solution for Injection, Exparel
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 30, 2026, 3:16 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

NCT05722938
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Trimodulin, Placebo (human albumin 1%)
Drug
Lead sponsor
Biotest
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
29
States / cities
Mobile, Alabama • Phoenix, Arizona • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 3:16 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects

NCT02696291
View directory record Official record
Conditions
Viral Infection
Interventions
UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution, UV-4B X mg (dose to be determined) oral solution, UV-4B Y mg (dose to be determined) oral solution, Placebo
Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 30, 2026, 3:16 PM EDT
Suspended Phase 2 Interventional

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

NCT04166552
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Patients will be randomized to receive EHP-101 or Placebo
Drug
Lead sponsor
Emerald Health Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 30, 2026, 3:16 PM EDT
Terminated Not applicable Interventional Results available

Surveillance Monitoring as an Alternative to Telemetry

NCT03039738
View directory record Official record
Conditions
Telemetry, Patient Monitoring
Interventions
Vital Sync IM & VPMP (Surveillance Monitoring), Telemetry Monitoring
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 30, 2026, 3:16 PM EDT
Withdrawn Phase 2 Interventional

Oxytocin Treatment for Alcohol Use Disorders

NCT03636555
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 30, 2026, 3:16 PM EDT
Completed Not applicable Interventional

Randomized Controlled Trial of Vaginal Cryotherapy for Pelvic Floor Myofascial Pain

NCT03885791
View directory record Official record
Conditions
Pelvic Floor Myofascial Pain, Pelvic Pain, Myofascial Pain
Interventions
vaginal cryotherapy
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 30, 2026, 3:16 PM EDT